Hepatitis C Virus-Related Acute and Chronic Hepatitis in Hemodialysis Patients

Nephron ◽  
1992 ◽  
Vol 61 (3) ◽  
pp. 322-323 ◽  
Author(s):  
M. Pluvio ◽  
A. Saggese ◽  
D. Cirillo ◽  
P. Castellino ◽  
R. Pempinello ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hemodialysis Patients ◽  
Acute And Chronic Hepatitis

scholarly journals Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nahla Mohamed Teama ◽  
Waleed Anwar Abdel-Mohsen ◽  
Ossama Ashraf Ahmed ◽  
Sarah Mohamed El Sayed ◽  
Ahmed Mohamed ElGhandour
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Case Control Study ◽  
Hemodialysis Patients ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus ◽  
Kidney Functions ◽  
Control Study

Abstract Background Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. This study aimed to evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without ribavirin in treatment of chronic hepatitis C Egyptian hemodialysis patients to compare it with the same treatment result in chronic hepatitis C Egyptian patients with normal renal functions. This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV-positive infection at the Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. Patients were divided into two groups: group I (control group) with 50 chronic hepatitis C virus patients with normal renal functions and group II (Case Group) with 50 chronic hepatitis C virus hemodialysis patients. Results 95.1% of prevalent hemodialysis patients achieved sustained virological response (SVR), while 100% of patients with normal kidney functions achieved sustained virological response. Most common side effects were hemoglobin drop, gastrointestinal disturbance, severe fatigue, and itching. Conclusion Ombitasvir, paritaprevir, and ritonavir are considered a safe and effective in treatment in HCV infection in patients on regular hemodialysis as in chronic hepatitis C virus infection patients with normal kidney functions.

The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C

1996 ◽  
Vol 74 (10) ◽  
pp. 583-588 ◽  
Author(s):  
H. M. Diepolder ◽  
R. Zachoval ◽  
R. M. Hoffmann ◽  
M.-C. Jung ◽  
T. Gerlach ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
T Lymphocytes ◽  
Chronic Hepatitis C ◽  
Acute And Chronic Hepatitis

scholarly journals Artificial Neural Network Model for Hepatitis C Stage Detection

2020 ◽  
Vol 1 (1) ◽  
pp. 11-16
Author(s):  
Dhiman Sarma ◽  
◽  
Tanni Mittra ◽  
Muntasir Hoq ◽  
Promila Haque ◽  
...  
Keyword(s):  
Neural Network ◽  
Artificial Neural Network ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Infected People ◽  
Egyptian Patients ◽  
Artificial Neural ◽  
Acute And Chronic Hepatitis ◽  
Prediction Evaluation

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). In 2015, WHO reports that 71 million people were living with HCV, and 1.34 million died. In 2017, 13.1 million infected people knew their diagnosis and around 5 million patients were treated. HCV can cause acute and chronic hepatitis, where 20% of chronic hepatitis progresses to final-stage chronic liver cancer. Currently, no vaccine of HCV exists, and no effective treatments are available for demolishing the progression of hepatitis C. So spotting the stages of the disease is essential for diagnostic and therapeutic management of infected patients. This paper attempts to detect stages of hepatitis C virus so that further diagnosis and medication of hepatitis patients can be prescribed. It uses a supervised artificial neural network to make a prediction. Evaluation of results is done by cross-validation using the holdout method. Hepatitis C Egyptian-patients' dataset from UCI Machine Learning Repository is used for feeding the algorithms. The research succeeds to detect the hepatitis C stages and achieves an accuracy of 97%.

scholarly journals Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection

JGH Open ◽  
2017 ◽  
Vol 1 (4) ◽  
pp. 148-152 ◽  
Author(s):  
Taiga Otsuka ◽  
Yasunori Kawaguchi ◽  
Toshihiko Mizuta ◽  
Yasushi Ide ◽  
Futa Koga ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hemodialysis Patients ◽  
Virus Genotype ◽  
Genotype 1B ◽  
Chronic Hepatitis C Virus
Sign in / Sign up

Export Citation Format

Share Document